Sosei Group Corp to Discuss Newly Announced Collaboration with Neurocrine Biosciences Investor Briefing Transcript
[Interpreted] Good Morning, everyone. Thank you for joining us today despite the early morning. From now on we will start the briefing session about the license agreement with new client which was announced on day before yesterday. So I am Hironoshin Nomura, manager of IR and Corporate Strategy department for Sosei Group. (technical difficulty) moderator for today, thank you very much.
Regarding the details of the alliance, we posted an explanation [booklet] on our website a day before yesterday. So in order to answer as many questions as possible today, we will place the explanation with the video and the presentation material is posted on our Home page.
And today, we have from our company CEO, Shinichi Tamura; CFO, Chris Cargill; and Chief Medical Office Tim Tasker, all participating and present at this time.
Please check the explanation with the video and the presentation material posted on our Home page. I would like to proceed (technical difficulty) focusing on questions and answers. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |